Philadelphia, PA · Founded 2017 · Privately Held (backing)
Developer of non-nucleotide small-molecule inhibitors designed for the treatment of cancer and infectious diseases. Avammune Therapeutics is based in Philadelphia, PA and was founded in 2017. Its last reported valuation was $33 million in May 2025. It has raised $18.5 million.
Last reported valuation
$33.0M
Oct 2026
Priced at
—
Total raised
$18.5M
Last round
—
Team — not yet on record
No current team members for Avammune Therapeutics are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Avammune Therapeutics with a free account
·Watch Avammune Therapeutics: the Monday email on marks, rounds and moves
